A new study has confirmed the superiority of brentuximab vedotin (Adcetris, Seagen) plus doxorubicin, vinblastine and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) for the first-line treatment of stage III and IV classic Hodgkin lymphoma (N Engl J Med 2022;387:310-320).
With six years of follow-up, results of the phase 3 ECHELON-1 trial showed an overall survival of 93.9% for patients who received the CD30-directed antibody?drug conjugate compared with
SEPTEMBER 7, 2022